Michael Evans, PhD

Title(s)Assistant Professor, Radiology
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Saint Mary's College of MarylandBA2001Chemistry
    The Scripps Research InstitutePhD2007Chemistry
    Memorial Sloan Kettering Cancer CenterPostdoctoral2013Human Oncology and Pathogenesis Program
    Collapse Awards and Honors
    American Cancer Society2017  - 2021Research Scholar Award
    American Brain Tumor Association2017  - 2018Discovery Award
    UCSF2016  - 2018Brain Tumor SPORE Developmental Research Project
    UCSF Academic Senate2016  - 2017Team Science Award
    Helen Diller Family Comprehensive Cancer Center2016  - 2017Precision Imaging of Cancer and Therapy Pilot Award
    DOD Prostate Cancer Research Program2015  - 2017Idea Development Award
    UCSF Academic Senate2014  - 2015Pilot Award
    Prostate Cancer Foundation2013  - 2016David H. Koch Young Investigator Award
    National Cancer Institute2012  - 2017Pathway to Independence Award
    Imaging and Radiation Sciences Brigde Program, MSKCC2012  - 2014Research Grant
    Imaging and Radiation Sciences Bridge Program, Memorial Sloan Kettering Cancer Center2011Research Award
    Brain Tumor Center of Memorial Sloan Kettering Cancer Center2011Research Award
    National Institutes of Health and Memorial Sloan Kettering Cancer Center2007  - 2010R25 Fellowship

    Collapse Overview 
    Collapse Overview
    Michael Evans, PhD, is an Assistant Professor in Residence in the Department of Radiology and Biomedical Imaging at the University of California, San Francisco. He is an experienced chemical biologist with a focus on molecular imaging and organic chemistry. Dr. Evans earned a BA in Chemistry from St. Mary’s College, Maryland and he obtained his PhD in Organic Chemistry from The Scripps Research Institute in La Jolla, California under the supervision of Professor Benjamin Cravatt, followed by postdoctoral fellowship in Molecular Imaging from the Memorial Sloan Kettering Cancer Center in New York under the supervision of Professors Charles Sawyers and Jason Lewis. In October 2013, Dr. Evans accepted the Assistant Professor in Residence position at UCSF.

    Dr. Evans specializes in small molecule synthesis, proteomics, and preclinical development and translation of new radiotracers, including antibody based radiotracers. By combining his expertise in chemical biology and molecular imaging, Dr. Evans and his group seek to discover and exploit for imaging biomarkers directly regulated by central oncogenes. To date, he has developed biomarkers measuring the activity of the androgen receptor and MYC in prostate cancer, and his group is now actively developing new imaging biomarkers to other important oncogenes.

    Dr. Evans is a member of the American Chemical Society, the American Association for Cancer Research, the Society of Nuclear Medicine and Molecular Imaging, and the World Molecular Imaging Society. He has been invited nationally and internationally to lecture about his research. Dr. Evans has published over 35 peer-reviewed articles, 10 abstracts, and is a co-inventor on 4 patents. Dr. Evans also is the principle investigator or co-investigator on six human trials focused on new strategies for imaging solid tumors. Dr. Evans was a scientific co-founder and previously served on the scientific advisory board of ORIC Pharmaceuticals, Inc.

    Chemical Biology, Molecular Imaging, Organic Chemistry, Cancer Biology, Positron Emission Tomography

    Small molecule synthesis, proteomics, preclinical development of radiotracers, translation of radiotracers, bioconjugation chemistry.

    Professional Interests:
    Cancer, molecular imaging of oncogene signaling with positron emission tomography, biomarkers, proteomics, organic chemistry, chemical biology, antibody development, prostate, brain, breast, oncogenes, androgen receptor, MYC, PI3K, tumor suppressors, signaling pathways, serum biomarkers, nuclear medicine

    Education and Training:
    • Bachelor of Art: St. Mary’s College, St. Mary’s City, Maryland - Chemistry
    • Doctor of Philosophy: The Scripps Research Institute, La Jolla, California - Organic Chemistry
    • Postdoctoral Fellowship: Memorial Sloan Kettering Cancer Center, New York - Molecular Imaging

    Collapse Research 
    Collapse Research Activities and Funding
    Precision Targeting of Castration-Resistant Prostate Cancer with a Novel Ferrous IronDependent Therapeutic Delivery and Tumor Imaging Strategy
    Prostate Cancer Research Program W81XWH-18-1-0763Oct 15, 2018 - Oct 14, 2021
    Role: co-Principal Investigator
    Development of a translational imaging tool as a predictive biomarker for anti-PD-1/PD-L1 immunotherapies
    NIH/NIBIB R01EB025207Jul 1, 2018 - Mar 31, 2022
    Role: Principal Investigator
    Development and translation of a novel radioligand to measure pathological changes in glucocorticoid receptor expression in the brain
    NIH/NIMH R01MH115043Dec 1, 2017 - Nov 30, 2020
    Role: Principal Investigator
    Developing 68Ga-citrate PET/MR to distinguish viable tumor from psuedoprogression
    American Brain Tumor Association DG1700008Jul 31, 2017 - Jun 29, 2018
    Role: PI
    Development of a biomarker for imaging mTORC1 activity with PET
    American Cancer Society 130635-RSG-17-005-01-CCEJul 1, 2017 - Jun 30, 2021
    Role: PI
    Annotating MYC status in treatment resistant metastatic castration resistant prostate cancer with Gallium-68 citrate PET
    Department of Defense Prostate Cancer Research Program W81XWH-16-1-0469Aug 30, 2016 - Aug 31, 2019
    Role: Co-I
    Development of a radioligand to measure glucocorticoid receptor expression in enzalutamide resistant prostate cancer
    Department of Defense Prostate Cancer Research Program W81XWH-15-1-0552Sep 28, 2015 - Sep 29, 2017
    Role: PI
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH/NCI R00CA172695Jan 1, 2014 - Dec 31, 2016
    Role: Principal Investigator
    Annotating Oncogene Status in Prostate Cancer with Zr-89-transferrin PET
    NIH/NCI R01CA176671Apr 1, 2013 - Mar 31, 2018
    Role: Co-Principal Investigator
    Noninvasive measurement of oncogenic signaling pathways with 89Zr-transferrin
    NIH/NCI K99CA172695Jan 3, 2013 - Dec 31, 2014
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse In The News
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Pai CS, Simons DM, Lu X, Evans M, Wei J, Wang YH, Chen M, Huang J, Park C, Chang A, Wang J, Westmoreland S, Beam C, Banach D, Bowley D, Dong F, Seagal J, Ritacco W, Richardson PL, Mitra S, Lynch G, Bousquet P, Mankovich J, Kingsbury G, Fong L. Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity. J Clin Invest. 2019 Jan 02; 129(1):349-363. PMID: 30530991.
      View in: PubMed
    2. Behr SC, Villanueva-Meyer JE, Li Y, Wang YH, Wei J, Moroz A, Lee JK, Hsiao JC, Gao KT, Ma W, Cha S, Wilson DM, Seo Y, Nelson SJ, Chang SM, Evans MJ. Targeting iron metabolism in high-grade glioma with 68Ga-citrate PET/MR. JCI Insight. 2018 Nov 02; 3(21). PMID: 30385712.
      View in: PubMed
    3. Moroz A, Lee CY, Wang YH, Hsiao JC, Sevillano N, Truillet C, Craik CS, Fong L, Wang CI, Evans MJ. A Preclinical Assessment of 89Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with 89Zr-C4. Bioconjug Chem. 2018 Oct 17; 29(10):3476-3482. PMID: 30227708.
      View in: PubMed
    4. Lux F, Tran VL, Thomas E, Dufort S, Rossetti F, Martini M, Truillet C, Doussineau T, Bort G, Denat F, Boschetti F, Angelovski G, Detappe A, Crémillieux Y, Mignet N, Doan BT, Larrat B, Meriaux S, Barbier E, Roux S, Fries P, Müller A, Abadjian MC, Anderson C, Canet-Soulas E, Bouziotis P, Barberi-Heyob M, Frochot C, Verry C, Balosso J, Evans M, Sidi-Boumedine J, Janier M, Butterworth K, McMahon S, Prise K, Aloy MT, Ardail D, Rodriguez-Lafrasse C, Porcel E, Lacombe S, Berbeco R, Allouch A, Perfettini JL, Chargari C, Deutsch E, Le Duc G, Tillement O. AGuIX® from bench to bedside-Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. Br J Radiol. 2018 Sep 18; 20180365. PMID: 30226413.
      View in: PubMed
    5. Henry KE, Dacek MM, Dilling TR, Caen JD, Fox IL, Evans MJ, Lewis JS. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. Clin Cancer Res. 2019 Jan 01; 25(1):166-176. PMID: 30228208.
      View in: PubMed
    6. Afshar-Oromieh A, Debus N, Uhrig M, Hope TA, Evans MJ, Holland-Letz T, Giesel FL, Kopka K, Hadaschik B, Kratochwil C, Haberkorn U. Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2045-2054. PMID: 29980832.
      View in: PubMed
    7. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 May 02; 10(439). PMID: 29720449.
      View in: PubMed
    8. Truillet C, Parker MFL, Huynh LT, Wei J, Jami KM, Wang YH, Shen YS, Sriram R, Wilson DM, Kurhanewicz J, Evans MJ. Measuring glucocorticoid receptor expression in vivo with PET. Oncotarget. 2018 Apr 17; 9(29):20399-20408. PMID: 29755660.
      View in: PubMed
    9. Martinko AJ, Truillet C, Julien O, Diaz JE, Horlbeck MA, Whiteley G, Blonder J, Weissman JS, Bandyopadhyay S, Evans MJ, Wells JA. Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 2018 Jan 23; 7. PMID: 29359686.
      View in: PubMed
    10. Truillet C, Oh HLJ, Yeo SP, Lee CY, Huynh LT, Wei J, Parker MFL, Blakely C, Sevillano N, Wang YH, Shen YS, Olivas V, Jami KM, Moroz A, Jego B, Jaumain E, Fong L, Craik CS, Chang AJ, Bivona TG, Wang CI, Evans MJ. Imaging PD-L1 Expression with ImmunoPET. Bioconjug Chem. 2018 01 17; 29(1):96-103. PMID: 29125731.
      View in: PubMed
    11. de Jesus Cortez F, Nguyen P, Truillet C, Tian B, Kuchenbecker KM, Evans MJ, Webb P, Jacobson MP, Fletterick RJ, England PM. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chem Biol. 2017 12 15; 12(12):2934-2939. PMID: 28981251.
      View in: PubMed
    12. Lue HW, Podolak J, Kolahi K, Cheng L, Rao S, Garg D, Xue CH, Rantala JK, Tyner JW, Thornburg KL, Martinez-Acevedo A, Liu JJ, Amling CL, Truillet C, Louie SM, Anderson KE, Evans MJ, O'Donnell VB, Nomura DK, Drake JM, Ritz A, Thomas GV. Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes Dev. 2017 10 15; 31(20):2067-2084. PMID: 29138276.
      View in: PubMed
    13. Henry KE, Dilling TR, Abdel-Atti D, Edwards KJ, Evans MJ, Lewis JS. Noninvasive 89Zr-Transferrin PET Shows Improved Tumor Targeting Compared with 18F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. J Nucl Med. 2018 Jan; 59(1):51-57. PMID: 28848040.
      View in: PubMed
    14. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. PMID: 28592703.
      View in: PubMed
    15. Mari Aparici C, Behr SC, Seo Y, Kelley RK, Corvera C, Gao KT, Aggarwal R, Evans MJ. Imaging Hepatocellular Carcinoma With 68Ga-Citrate PET: First Clinical Experience. Mol Imaging. 2017 Jan-Dec; 16:1536012117723256. PMID: 28893116.
      View in: PubMed
    16. Truillet C, Cunningham JT, Parker MFL, Huynh LT, Conn CS, Ruggero D, Lewis JS, Evans MJ. Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clin Cancer Res. 2017 Jun 15; 23(12):3045-3052. PMID: 28007777.
      View in: PubMed
    17. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. PMID: 27184068.
      View in: PubMed
    18. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. PMID: 27660139.
      View in: PubMed
    19. Truillet C, Thomas E, Lux F, Huynh LT, Tillement O, Evans MJ. Synthesis and Characterization of (89)Zr-Labeled Ultrasmall Nanoparticles. Mol Pharm. 2016 07 05; 13(7):2596-601. PMID: 27266800.
      View in: PubMed
    20. Liu W, Truillet C, Flavell RR, Brewer TF, Evans MJ, Wilson DM, Chang CJ. A reactivity-based [18F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chem Sci. 2016 Aug 01; 7(8):5503-5507. PMID: 30034690.
      View in: PubMed
    21. Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 06 17; 11(6):1587-94. PMID: 27008570.
      View in: PubMed
    22. Carroll VN, Truillet C, Shen B, Flavell RR, Shao X, Evans MJ, VanBrocklin HF, Scott PJ, Chin FT, Wilson DM. [(11)C]Ascorbic and [(11)C]dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chem Commun (Camb). 2016 Apr 07; 52(27):4888-90. PMID: 26963495; PMCID: PMC4854297 [Available on 04/07/17].
    23. Liu, W.; Truillet, C.; Flavell, R.R.; Brewer, T.; Evans, M.J.; Wilson, D.M.; Chang, C.A Reactivity-Based [18F]FDG Probe for In Vivo Formaldehyde Imaging Using Positron Emission Tomography. Chemical Science. 2016; (7):5503-5507.
    24. Carroll, V.N.; Truillet, C.; Shen, B.; Flavell, R.R.; Shao, X.; Evans, M.J.; VanBrocklin, H.F.; Scott, P.H.J.; Chin, F.T.; Wilson, D.M.11C-Ascorbic and 11C-dehydroascorbic acid, an endogenous redox pair for sensing reactive oxygen species using positron emission tomography. Chemical Communications. 2016; 27(52):4888-4890.
    25. Doran MG, Carnazza KE, Steckler JM, Spratt DE, Truillet C, Wongvipat J, Sawyers CL, Lewis JS, Evans MJ. Applying 8?Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Mol Pharm. 2016 Feb 01; 13(2):683-8. PMID: 26725682; PMCID: PMC4738321.
    26. Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8. PMID: 26649808; PMCID: PMC4854293.
    27. Spratt DE, Evans MJ, Davis BJ, Doran MG, Lee MX, Shah N, Wongvipat J, Carnazza KE, Klee GG, Polkinghorn W, Tindall DJ, Lewis JS, Sawyers CL. Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res. 2015 Nov 15; 75(22):4688-96. PMID: 26432404; PMCID: PMC4651750 [Available on 11/15/16].
    28. Gerdtsson A, Poon JB, Thorek DL, Mucci LA, Evans MJ, Scardino P, Abrahamsson PA, Nilsson P, Manjer J, Bjartell A, Malm J, Vickers A, Freedland SJ, Lilja H, Ulmert D. Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. Eur Urol. 2015 Dec; 68(6):1076-82. PMID: 25794458; PMCID: PMC4573834.
    29. Doran MG, Watson PA, Cheal SM, Spratt DE, Wongvipat J, Steckler JM, Carrasquillo JA, Evans MJ, Lewis JS. Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. J Nucl Med. 2014 Dec; 55(12):2045-9. PMID: 25453051; PMCID: PMC4410715.
    30. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. Cabozantinib Resolves Bone Scans in Tumor-Naïve Mice Harboring Skeletal Injuries. Mol Imaging. 2014 Oct 01; 13(8):7290201400026. PMID: 28650280.
      View in: PubMed
    31. Huang CH, Lujambio A, Zuber J, Tschaharganeh DF, Doran MG, Evans MJ, Kitzing T, Zhu N, de Stanchina E, Sawyers CL, Armstrong SA, Lewis JS, Sherr CJ, Lowe SW. CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes Dev. 2014 Aug 15; 28(16):1800-14. PMID: 25128497; PMCID: PMC4197965.
    32. Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, Zanzonico P, Larson SM. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014 May; 41(5):985-94. PMID: 24604591; PMCID: PMC4120276.
    33. Doran MG, Spratt DE, Wongvipat J, Ulmert D, Carver BS, Sawyers CL, Evans MJ. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries. Mol Imaging. 2014; 13. PMID: 25248353; PMCID: PMC4545649.
    34. Zeglis BM, Houghton JL, Evans MJ, Viola-Villegas N, Lewis JS. Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. Inorg Chem. 2014 Feb 17; 53(4):1880-99. PMID: 24313747; PMCID: PMC4151561.
    35. Viola-Villegas NT, Rice SL, Carlin S, Wu X, Evans MJ, Sevak KK, Drobjnak M, Ragupathi G, Sawada R, Scholz WW, Livingston PO, Lewis JS. Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. J Nucl Med. 2013 Nov; 54(11):1876-82. PMID: 24029655; PMCID: PMC4274751.
    36. Thorek DL, Evans MJ, Carlsson SV, Ulmert D, Lilja H. Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. Thromb Haemost. 2013 Sep; 110(3):484-92. PMID: 23903407; PMCID: PMC4029064.
    37. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013 Apr 09; 2:e00499. PMID: 23580326; PMCID: PMC3622181.
    38. Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma. Mol Imaging. 2013 Jan-Feb; 12(1):67-73. PMID: 23348793.
      View in: PubMed
    39. Evans MJ, Holland JP, Rice SL, Doran MG, Cheal SM, Campos C, Carlin SD, Mellinghoff IK, Sawyers CL, Lewis JS. Imaging tumor burden in the brain with 89Zr-transferrin. J Nucl Med. 2013 Jan; 54(1):90-5. PMID: 23236019; PMCID: PMC3747823.
    40. Evans MJ. Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. Cancer Discov. 2012 Nov; 2(11):985-94. PMID: 23043150; PMCID: PMC3508522.
    41. Holland JP, Evans MJ, Rice SL, Wongvipat J, Sawyers CL, Lewis JS. Annotating MYC status with 89Zr-transferrin imaging. Nat Med. 2012 Oct; 18(10):1586-91. PMID: 23001181; PMCID: PMC3521603.
    42. Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL. Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. Cancer Discov. 2012 Apr; 2(4):320-7. PMID: 22576209; PMCID: PMC3351274.
    43. Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Björk T, Gerdtsson A, Bjartell A, Gjertsson P, Höglund P, Lomsky M, Ohlsson M, Richter J, Sadik M, Morris MJ, Scher HI, Sjöstrand K, Yu A, Suurküla M, Edenbrandt L, Larson SM. A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. Eur Urol. 2012 Jul; 62(1):78-84. PMID: 22306323; PMCID: PMC3402084.
    44. Stelter L, Evans MJ, Jungbluth AA, Zanzonico P, Ritter G, Ku T, Rosenfeld E, Bomalaski JS, Old L, Larson SM. Novel mechanistic insights into arginine deiminase pharmacology suggest 18F-FDG is not suitable to evaluate clinical response in melanoma. J Nucl Med. 2012 Feb; 53(2):281-6. PMID: 22228793.
      View in: PubMed
    45. Evans MJ, Smith-Jones PM, Wongvipat J, Navarro V, Kim S, Bander NH, Larson SM, Sawyers CL. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A. 2011 Jun 07; 108(23):9578-82. PMID: 21606347.
      View in: PubMed
    46. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 06; 107(14):6459-64. PMID: 20308550; PMCID: PMC2851999.
    47. Evans MJ, Morris GM, Wu J, Olson AJ, Sorensen EJ, Cravatt BF. Mechanistic and structural requirements for active site labeling of phosphoglycerate mutase by spiroepoxides. Mol Biosyst. 2007 Jul; 3(7):495-506. PMID: 17579775.
      View in: PubMed
    48. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, Patapoutian A. Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature. 2007 Feb 01; 445(7127):541-5. PMID: 17237762.
      View in: PubMed
    49. Evans MJ, Cravatt BF. Mechanism-based profiling of enzyme families. Chem Rev. 2006 Aug; 106(8):3279-301. PMID: 16895328.
      View in: PubMed
    50. Evans MJ, Saghatelian A, Sorensen EJ, Cravatt BF. Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling. Nat Biotechnol. 2005 Oct; 23(10):1303-7. PMID: 16200062.
      View in: PubMed